Effects of incretin-based therapy on CV complications In line with previous evidence accrued in patients with T2D 83 , recent data demonstrated for the first time that incretin-based therapy was associated with CV risk reduction in patients with overweight or obesity with normoglycemia or prediabetes
Ranjan A, Ramachandran S, Gupta N, Kaushik I, Wright S, Srivastava S, et al
Their key message is to be wary of all substitute weight loss medications from compounding pharmacies or medical spas
Patients should consult their doctor if they experience allergic reactions or unusual symptoms
These changes contribute to a healthier heart and a reduced likelihood of cardiovascular events
We can't totally predict if we're going to nail it the first time